Home LiteratureArticle Details
PMID: 12696997 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Glutamate receptors and Parkinson's disease: opportunities for intervention.

Drugs & aging ·Vol. 20 ·No. 5 ·2003-00-00 ·Pages 377-97

Marino MJ, Valenti O, Conn PJ

Abstract

Parkinson's disease is a debilitating neurodegenerative movement disorder that is the result of a degeneration of dopaminergic neurons in the substantia nigra pars compacta. The resulting loss of striatal dopaminergic tone is believed to underlie a series of changes in the circuitry of the basal ganglia that ultimately lead to severe motor disturbances due to excessive basal ganglia outflow. Glutamate plays a central role in the disruption of normal basal ganglia function, and it has been hypothesised that agents acting to restore normal glutamatergic function may provide therapeutic interventions that bypass the severe motor side effects associated with current dopamine replacement strategies. Analysis of the effects of glutamate receptor ligands in the basal ganglia circuit suggests that both ionotropic and metabotropic glutamate receptors could have antiparkinsonian actions. In particular, NMDA receptor antagonists that selectively target the NR2B subunit and antagonists of the metabotropic glutamate receptor mGluR5 appear to hold promise and deserve future attention.

MeSH Terms
Antiparkinson Agents/therapeutic use Excitatory Amino Acid Antagonists/therapeutic use Humans Parkinson Disease/drug therapy,metabolism Receptors, Glutamate/metabolism
Chemicals
Antiparkinson Agents Excitatory Amino Acid Antagonists Receptors, Glutamate
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Marino Michael J
Department of Neuroscience, Merck Research Laboratories, West Point, Pennsylvania 19486-0004, USA.
Valenti Ornella
Conn P Jeffrey
References (222)
222 references, click to expand
  1. Subcellular and subsynaptic localization of presynaptic and postsynaptic kainate receptor subunits in the monkey striatum.
    J Neurosci. 2001 Nov 15;21(22):8746-57 PMID: 11698586
  2. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Neurology. 1998 May;50(5):1323-6 PMID: 9595981
  3. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.
    J Neurochem. 1992 Aug;59(2):733-9 PMID: 1629743
  4. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease.
    J Neurosurg. 1992 Jan;76(1):53-61 PMID: 1727169
  5. Subthalamic nucleus cell firing in the 6-OHDA-treated rat: basal activity and response to haloperidol.
    Brain Res. 1992 Sep 11;590(1-2):291-9 PMID: 1422838
  6. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane.
    J Neurosci. 2001 Aug 1;21(15):5546-58 PMID: 11466426
  7. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
    Mov Disord. 2001 May;16(3):515-20 PMID: 11391748
  8. [Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study].
    Dtsch Med Wochenschr. 1984 Jun 22;109(25):987-90 PMID: 6734455
  9. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity.
    Annu Rev Neurosci. 1988;11:61-80 PMID: 2452598
  10. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
    Clin Neuropharmacol. 2000 Mar-Apr;23(2):82-5 PMID: 10803797
  11. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus.
    J Neurosci. 2000 Nov 1;20(21):7871-9 PMID: 11050106
  12. Two populations of kainate receptors with separate signaling mechanisms in hippocampal interneurons.
    Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1293-8 PMID: 10655524
  13. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.
    Eur J Pharmacol. 1991 Apr 25;206(4):297-300 PMID: 1717296
  14. GluR1 glutamate receptor subunit is regulated differentially in the primate basal ganglia following nigrostriatal dopamine denervation.
    J Neurochem. 2000 Mar;74(3):1166-74 PMID: 10693949
  15. The glycine binding site of the N-methyl-D-aspartate receptor subunit NR1: identification of novel determinants of co-agonist potentiation in the extracellular M3-M4 loop region.
    Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6031-6 PMID: 8650214
  16. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    J Pharmacol Exp Ther. 1999 Sep;290(3):1034-40 PMID: 10454475
  17. The glutamate receptor ion channels.
    Pharmacol Rev. 1999 Mar;51(1):7-61 PMID: 10049997
  18. The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue.
    J Neural Transm Suppl. 1995;46:131-7 PMID: 8821048
  19. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
    Mol Pharmacol. 2000 Feb;57(2):342-52 PMID: 10648644
  20. Identification of amino acids in the N-methyl-D-aspartate receptor NR1 subunit that contribute to the glycine binding site.
    Mol Pharmacol. 1995 Feb;47(2):374-80 PMID: 7870047
  21. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.
    Synapse. 2000 Jun 15;36(4):267-74 PMID: 10819904
  22. Oxidative stress and genetics in the pathogenesis of Parkinson's disease.
    Neurobiol Dis. 2000 Aug;7(4):240-50 PMID: 10964596
  23. Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones.
    Br J Pharmacol. 1997 Mar;120(6):1007-14 PMID: 9134210
  24. Activation of group III metabotropic glutamate receptors depresses glutamatergic transmission at corticostriatal synapse.
    Neuropharmacology. 1997 Jun;36(6):845-51 PMID: 9225312
  25. Pharmacological characterization of the metabotropic glutamate receptor inhibiting D-[3H]-aspartate output in rat striatum.
    Br J Pharmacol. 1993 Dec;110(4):1407-12 PMID: 8306080
  26. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection.
    Ann Neurol. 1998 Sep;44(3 Suppl 1):S175-88 PMID: 9749591
  27. Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes.
    Eur J Pharmacol. 1995 Apr 13;277(1):117-21 PMID: 7635167
  28. N-methyl-D-aspartate-activated channels of mouse central neurones in magnesium-free solutions.
    J Physiol. 1988 May;399:207-26 PMID: 2457087
  29. mRNA distribution in adult human brain of GRIN2B, a N-methyl-D-aspartate (NMDA) receptor subunit.
    Neurosci Lett. 1997 Dec 12;239(1):49-53 PMID: 9547169
  30. Coordinate regulation of metabotropic glutamate receptors.
    Curr Opin Neurobiol. 2001 Jun;11(3):357-62 PMID: 11399435
  31. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Synapse. 1997 Aug;26(4):381-91 PMID: 9215597
  32. Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3.
    J Neurophysiol. 1995 Mar;73(3):1076-83 PMID: 7608756
  33. LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats.
    Naunyn Schmiedebergs Arch Pharmacol. 1998 Oct;358(4):500-2 PMID: 9826074
  34. Amantadine in the treatment of Parkinson's disease.
    JAMA. 1969 May 19;208(7):1168-70 PMID: 5818715
  35. Linking Hebb's coincidence-detection to memory formation.
    Curr Opin Neurobiol. 2000 Apr;10(2):266-73 PMID: 10753792
  36. Activation of group I metabotropic glutamate receptors produces a direct excitation and disinhibition of GABAergic projection neurons in the substantia nigra pars reticulata.
    J Neurosci. 2001 Sep 15;21(18):7001-12 PMID: 11549710
  37. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
    J Neural Transm Park Dis Dement Sect. 1991;3(3):203-13 PMID: 1835581
  38. Behavioural pharmacology of the non-competitive NMDA antagonists dextrorphan and ADCI: relations between locomotor stimulation, anticataleptic potential and forebrain dopamine metabolism.
    Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):767-73 PMID: 9205962
  39. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease.
    Arch Neurol. 2001 Oct;58(10):1660-8 PMID: 11594926
  40. The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats.
    Eur J Pharmacol. 1996 Oct 31;314(3):307-11 PMID: 8957251
  41. Expression of glutamate receptors in the human and rat basal ganglia: effect of the dopaminergic denervation on AMPA receptor gene expression in the striatopallidal complex in Parkinson's disease and rat with 6-OHDA lesion.
    J Comp Neurol. 1996 May 13;368(4):553-68 PMID: 8744443
  42. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat.
    Exp Neurol. 1999 Jan;155(1):42-8 PMID: 9918703
  43. Role of the subthalamic nucleus in the regulation of nigral dopamine neuron activity.
    Synapse. 1992 Dec;12(4):287-303 PMID: 1465742
  44. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
    Arch Neurol. 1999 Nov;56(11):1383-6 PMID: 10555659
  45. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys.
    Ann Neurol. 1991 Nov;30(5):717-23 PMID: 1662477
  46. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion.
    Neuroscience. 1999 Jan;88(1):1-16 PMID: 10051185
  47. Modulation of NMDA receptor function: implications for vertebrate neural development.
    FASEB J. 1994 Jul;8(10):745-52 PMID: 8050674
  48. Roles of NMDA receptor activity and nitric oxide production in brain development.
    Brain Res Brain Res Rev. 2000 Apr;32(2-3):476-509 PMID: 10760552
  49. A controlled trial of remacemide hydrochloride in Huntington's disease.
    Mov Disord. 1996 May;11(3):273-7 PMID: 8723144
  50. Kainate receptor modulation of GABA release involves a metabotropic function.
    Neuron. 1998 Jun;20(6):1211-8 PMID: 9655508
  51. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced.
    Brain Res. 1988 Jun 7;451(1-2):205-12 PMID: 2472189
  52. Genetic regulation of glutamate receptor ion channels.
    Annu Rev Pharmacol Toxicol. 1999;39:221-41 PMID: 10331083
  53. Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine.
    J Neurochem. 1992 Jul;59(1):245-51 PMID: 1319468
  54. MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats.
    J Neurochem. 1992 May;58(5):1979-982 PMID: 1560247
  55. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions.
    Trends Neurosci. 1994 Jun;17(6):228-33 PMID: 7521083
  56. Subthalamic nucleus neurons switch from single-spike activity to burst-firing mode.
    J Neurosci. 1999 Jan 15;19(2):599-609 PMID: 9880580
  57. Ionotropic and metabotropic GABA and glutamate receptors in primate basal ganglia.
    J Chem Neuroanat. 2001 Jul;22(1-2):13-42 PMID: 11470552
  58. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists.
    Eur J Pharmacol. 1993 Jun 11;237(1):1-7 PMID: 8359205
  59. Levodopa strengths and weaknesses.
    Neurology. 2002 Feb 26;58(4 Suppl 1):S19-32 PMID: 11909982
  60. NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms.
    Trends Neurosci. 1993 Dec;16(12):521-7 PMID: 7509523
  61. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
    Neurology. 2000 Apr 25;54(8):1589-95 PMID: 10762498
  62. A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations.
    Clin Neuropharmacol. 2001 May-Jun;24(3):133-8 PMID: 11391123
  63. Effect of RNA editing and subunit co-assembly single-channel properties of recombinant kainate receptors.
    J Physiol. 1996 Apr 1;492 ( Pt 1):129-42 PMID: 8730589
  64. Excitotoxicity and the NMDA receptor--still lethal after eight years.
    Trends Neurosci. 1995 Feb;18(2):57-8 PMID: 7537407
  65. Argiotoxin detects molecular differences in AMPA receptor channels.
    Neuron. 1993 Jun;10(6):1131-40 PMID: 7686380
  66. Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide.
    Epilepsy Res. 1992 Jun;12(1):9-20 PMID: 1388119
  67. An alanine residue in the M3-M4 linker lines the glycine binding pocket of the N-methyl-D-aspartate receptor.
    J Biol Chem. 1997 Feb 7;272(6):3532-7 PMID: 9013601
  68. A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease.
    J Neurol Neurosurg Psychiatry. 1992 Jul;55(7):630-1 PMID: 1386383
  69. Pathogenesis of Parkinson's disease.
    Curr Opin Investig Drugs. 2001 May;2(5):657-62 PMID: 11569943
  70. Cell-type specificity of mGluR activation in striatal neuronal subtypes.
    Amino Acids. 2000;19(1):119-29 PMID: 11026480
  71. The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys.
    Eur J Pharmacol. 1993 Apr 28;235(2-3):297-300 PMID: 7685291
  72. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats.
    Synapse. 2001 Oct;42(1):40-7 PMID: 11668589
  73. Intrastriatal and intrasubthalamic stimulation of metabotropic glutamate receptors: a behavioral and Fos immunohistochemical study.
    Neuroscience. 1995 May;66(1):55-65 PMID: 7637875
  74. Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia Nigra pars reticulata.
    J Neurosci. 2000 May 1;20(9):3085-94 PMID: 10777772
  75. Hippocampal synaptic plasticity and NMDA receptors: a role in information storage?
    Philos Trans R Soc Lond B Biol Sci. 1990 Aug 29;329(1253):187-204 PMID: 1978364
  76. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?
    Trends Neurosci. 1993 Apr;16(4):125-31 PMID: 7682343
  77. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease.
    Ann Neurol. 2001 Apr;49(4):525-9 PMID: 11310632
  78. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.
    Brain Res. 1996 Oct 14;736(1-2):202-5 PMID: 8930325
  79. Energetics in the pathogenesis of neurodegenerative diseases.
    Trends Neurosci. 2000 Jul;23(7):298-304 PMID: 10856939
  80. Adjuvant treatment of Parksinson's disease with budipine: a double-blind trial versus placebo.
    J Neurol. 1987 Jun;234(5):280-2 PMID: 3302121
  81. Relationships between the neuronal sodium/potassium pump and energy metabolism. Effects of K+, Na+, and adenosine triphosphate in isolated brain synaptosomes.
    J Gen Physiol. 1990 Apr;95(4):591-616 PMID: 2159972
  82. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications.
    Pharmacol Rev. 1998 Dec;50(4):597-664 PMID: 9860805
  83. Dorsal subthalamotomy for Parkinson's disease.
    Mov Disord. 2001 Jan;16(1):72-8 PMID: 11215596
  84. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
    Neurology. 1998 Jul;51(1):203-6 PMID: 9674803
  85. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice.
    J Neural Transm. 1989;75(3):221-6 PMID: 2538557
  86. Activation of groups I or III metabotropic glutamate receptors inhibits excitatory transmission in the rat subthalamic nucleus.
    Neuropharmacology. 2001 Jul;41(1):32-41 PMID: 11445183
  87. Metabotropic glutamate receptors and cell-type-specific vulnerability in the striatum: implication for ischemia and Huntington's disease.
    Exp Neurol. 1999 Jul;158(1):97-108 PMID: 10448421
  88. Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method.
    J Comp Neurol. 1987 Jun 15;260(3):435-52 PMID: 2439552
  89. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism.
    J Neurosci. 2002 Jul 1;22(13):5669-78 PMID: 12097518
  90. Mutational analysis of the glycine-binding site of the NMDA receptor: structural similarity with bacterial amino acid-binding proteins.
    Neuron. 1994 Jun;12(6):1291-300 PMID: 8011339
  91. Metabotropic glutamate agonist-induced rotation: a pharmacological, FOS immunohistochemical, and [14C]-2-deoxyglucose autoradiographic study.
    J Neurosci. 1997 Jun 1;17 (11):4415-25 PMID: 9151758
  92. Intrasubthalamic nucleus metabotropic glutamate receptor activation: a behavioral, Fos immunohistochemical and [14C]2-deoxyglucose autoradiographic study.
    Neuroscience. 2000;95(2):409-16 PMID: 10658620
  93. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group.
    Ann Neurol. 1992 Dec;32(6):782-8 PMID: 1471869
  94. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Ann Neurol. 1994 Jun;35(6):655-61 PMID: 8210221
  95. AMPA receptors: molecular and functional diversity.
    Prog Brain Res. 1998;116:153-70 PMID: 9932376
  96. Glutamate receptor RNA editing in vitro by enzymatic conversion of adenosine to inosine.
    Science. 1995 Mar 10;267(5203):1491-4 PMID: 7878468
  97. The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics.
    Brain. 2001 Sep;124(Pt 9):1777-90 PMID: 11522580
  98. (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses.
    J Med Chem. 1995 Aug 4;38(16):3138-45 PMID: 7636876
  99. Functional changes of the basal ganglia circuitry in Parkinson's disease.
    Prog Neurobiol. 2000 Sep;62(1):63-88 PMID: 10821982
  100. Antagonist properties of eliprodil and other NMDA receptor antagonists at rat NR1A/NR2A and NR1A/NR2B receptors expressed in Xenopus oocytes.
    Neurosci Lett. 1997 Feb 21;223(2):133-6 PMID: 9089691
  101. A trial of dextromethorphan in parkinsonian patients with motor response complications.
    Mov Disord. 1998 May;13(3):414-7 PMID: 9613730
  102. [Monotherapy of Parkinson's disease with budipine. A double blind comparison with amantadine].
    Fortschr Neurol Psychiatr. 2001 Feb;69(2):86-9 PMID: 11253562
  103. MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease.
    Eur J Pharmacol. 1990 Jul 17;182(3):611-2 PMID: 1977595
  104. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke.
    Stroke. 1999 Sep;30(9):1796-801 PMID: 10471426
  105. Experimental models and behavioural tests used in the study of Parkinson's disease.
    Physiol Res. 1995;44(3):143-50 PMID: 8869270
  106. Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice.
    J Neural Transm. 1989;77(1):65-71 PMID: 2545813
  107. Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease.
    Trends Neurosci. 1990 Jul;13(7):272-6 PMID: 1695402
  108. Activation of metabotropic glutamate receptors inhibits calcium currents and GABA-mediated synaptic potentials in striatal neurons.
    J Neurosci. 1994 Nov;14(11 Pt 1):6734-43 PMID: 7965074
  109. Acute pharmacologic blockade of dyskinesias in Parkinson's disease.
    Mov Disord. 1996 Sep;11(5):580-1 PMID: 8866502
  110. Antiparkinsonian actions of glutamate antagonists--alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms.
    J Neural Transm Park Dis Dement Sect. 1995;10(2-3):141-85 PMID: 9620061
  111. The GluR2 (GluR-B) hypothesis: Ca(2+)-permeable AMPA receptors in neurological disorders.
    Trends Neurosci. 1997 Oct;20(10):464-70 PMID: 9347614
  112. Magnesium gates glutamate-activated channels in mouse central neurones.
    Nature. 1984 Feb 2-8;307(5950):462-5 PMID: 6320006
  113. CP-101,606, a potent neuroprotectant selective for forebrain neurons.
    Eur J Pharmacol. 1997 Jul 23;331(2-3):117-26 PMID: 9274969
  114. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease.
    J Neural Transm Park Dis Dement Sect. 1992;4:277-82 PMID: 1388698
  115. Glutamate and Parkinson's disease.
    Ann Neurol. 1994 Jun;35(6):639 PMID: 7911652
  116. Presynaptic kainate receptors in the monkey striatum.
    Neuroscience. 1999;91(4):1195-200 PMID: 10391427
  117. Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression.
    J Pharmacol Exp Ther. 1992 Jan;260(1):402-8 PMID: 1346165
  118. Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit.
    Neuron. 1997 Mar;18(3):493-503 PMID: 9115742
  119. (RS)-alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid: wet dog shakes, catalepsy and body temperature changes in rats.
    Pharmacol Biochem Behav. 1981 Oct;15(4):545-9 PMID: 6170075
  120. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat.
    J Neurosci. 1994 May;14(5 Pt 2):3005-18 PMID: 8182455
  121. Effect of 6-OHDA injection on the AMPA glutamate receptor subunits in the substantia nigra of Sprague-Dawley rats.
    Neurosci Lett. 1998 Jan 23;241(1):1-4 PMID: 9502201
  122. MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain.
    Eur J Pharmacol. 1997 Aug 6;332(2):153-60 PMID: 9286616
  123. Mitochondrial complex I deficiency in Parkinson's disease.
    J Neurochem. 1990 Mar;54(3):823-7 PMID: 2154550
  124. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus.
    Neuroscience. 1996 May;72(1):105-15 PMID: 8730710
  125. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey.
    Neuropharmacology. 1989 Nov;28(11):1271-3 PMID: 2687716
  126. The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior.
    J Neural Transm Gen Sect. 1992;87(1):23-35 PMID: 1346965
  127. Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats.
    Eur J Pharmacol. 2000 Oct 20;406(3):403-10 PMID: 11040347
  128. The role of excitotoxicity in neurodegenerative disease: implications for therapy.
    Pharmacol Ther. 1999 Mar;81(3):163-221 PMID: 10334661
  129. Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease.
    J Neural Transm Suppl. 1992;38:55-64 PMID: 1491248
  130. The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations.
    Mov Disord. 1999 May;14(3):517-9 PMID: 10348483
  131. Activation of quisqualate metabotropic receptors reduces glutamate and GABA-mediated synaptic potentials in the rat striatum.
    Neurosci Lett. 1992 May 11;139(1):41-4 PMID: 1357603
  132. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders.
    Pharmacol Ther. 2000 Dec;88(3):427-35 PMID: 11337032
  133. Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action.
    Neurosci Biobehav Rev. 1997 Jul;21(4):469-75 PMID: 9195604
  134. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
    Exp Neurol. 2000 May;163(1):239-43 PMID: 10785463
  135. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats.
    Neuropharmacology. 2001 Sep;41(4):413-20 PMID: 11543761
  136. Subthalamic stimulation-induced synaptic responses in substantia nigra pars compacta dopaminergic neurons in vitro.
    J Neurophysiol. 1999 Aug;82(2):925-33 PMID: 10444687
  137. The NMDA receptor channel: molecular design of a coincidence detector.
    Recent Prog Horm Res. 1995;50:19-34 PMID: 7740157
  138. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
    Life Sci. 1985 Jul 1;36(26):2503-8 PMID: 2861548
  139. Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor.
    J Biol Chem. 1996 Apr 19;271(16):9603-11 PMID: 8621635
  140. Immunoblot analyses on the differential distribution of NR2A and NR2B subunits in the adult rat brain.
    Mol Cells. 1997 Dec 31;7(6):749-54 PMID: 9509416
  141. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study.
    Ann Neurol. 1996 Sep;40(3):355-66 PMID: 8797525
  142. Equilibrium and kinetic study of glycine action on the N-methyl-D-aspartate receptor in cultured mouse brain neurons.
    J Physiol. 1992 Sep;455:339-65 PMID: 1484357
  143. GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist.
    Neuropharmacology. 1999 Jan;38(1):109-19 PMID: 10193902
  144. Intraoperative microrecordings of the subthalamic nucleus in Parkinson's disease.
    Mov Disord. 2002;17 Suppl 3:S145-9 PMID: 11948769
  145. Identification of amino acid residues of the NR2A subunit that control glutamate potency in recombinant NR1/NR2A NMDA receptors.
    J Neurosci. 1998 Jan 15;18(2):581-9 PMID: 9425000
  146. Distinct functional roles of the metabotropic glutamate receptors 1 and 5 in the rat globus pallidus.
    J Neurosci. 2003 Jan 1;23 (1):122-30 PMID: 12514208
  147. Activation of group III mGluRs inhibits GABAergic and glutamatergic transmission in the substantia nigra pars reticulata.
    J Neurophysiol. 2001 May;85(5):1960-8 PMID: 11353013
  148. Prevalence of parkinsonian signs and associated mortality in a community population of older people.
    N Engl J Med. 1996 Jan 11;334(2):71-6 PMID: 8531961
  149. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.
    N Engl J Med. 2001 Sep 27;345(13):956-63 PMID: 11575287
  150. Behavioural pharmacology of glutamate receptors in the basal ganglia.
    Neurosci Biobehav Rev. 1997 Jul;21(4):381-92 PMID: 9195596
  151. NMDA receptor blockade reverses motor response alterations induced by levodopa.
    Neuroreport. 1994 Dec 20;5(18):2586-8 PMID: 7696610
  152. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors.
    Mol Pharmacol. 1993 Oct;44(4):851-9 PMID: 7901753
  153. Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice.
    J Neural Transm Gen Sect. 1994;97(3):175-85 PMID: 7873128
  154. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation.
    Lancet. 1995 Jan 14;345(8942):91-5 PMID: 7815888
  155. Differences in Ca2+ permeability of AMPA-type glutamate receptor channels in neocortical neurons caused by differential GluR-B subunit expression.
    Neuron. 1994 Jun;12(6):1281-9 PMID: 8011338
  156. The subthalamic nucleus, hemiballismus and Parkinson's disease: reappraisal of a neurosurgical dogma.
    Brain. 2001 Jan;124(Pt 1):5-19 PMID: 11133783
  157. Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism.
    Life Sci. 1990;47(18):PL91-7 PMID: 2250573
  158. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Exp Neurol. 2000 Sep;165(1):136-42 PMID: 10964492
  159. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. Parkinson Study Group.
    Neurology. 2000 Apr 25;54(8):1583-8 PMID: 10762497
  160. Activation of N-methyl-D-aspartate receptors by glycine: role of an aspartate residue in the M3-M4 loop of the NR1 subunit.
    Mol Pharmacol. 1996 Oct;50(4):701-8 PMID: 8863813
  161. Antiparkinsonian action of MK-801 on the reserpine-induced rigidity: a mechanomyographic analysis.
    J Neural Transm Park Dis Dement Sect. 1994;7(2):143-52 PMID: 7710666
  162. Alternative excitotoxic hypotheses.
    Neurology. 1992 Apr;42(4):733-8 PMID: 1314341
  163. Milacemide therapy for Parkinson's disease.
    Mov Disord. 1993;8(1):47-50 PMID: 8380487
  164. Molecular determinants of metabotropic glutamate receptor signaling.
    Trends Pharmacol Sci. 2001 Mar;22(3):114-20 PMID: 11239574
  165. Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit.
    Neuron. 1992 Jan;8(1):189-98 PMID: 1370372
  166. NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release.
    Trends Pharmacol Sci. 1995 Oct;16(10):356-9 PMID: 7491714
  167. Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones.
    Neuropharmacology. 1998 Jun;37(6):719-27 PMID: 9707285
  168. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates.
    Naunyn Schmiedebergs Arch Pharmacol. 1993 Dec;348(6):586-92 PMID: 7907775
  169. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex.
    Eur J Pharmacol. 1989 Aug 3;166(3):589-90 PMID: 2680528
  170. Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum.
    J Comp Neurol. 2000 Apr 17;419(4):407-21 PMID: 10742712
  171. Microelectrode-guided pallidotomy: technical approach and its application in medically intractable Parkinson's disease.
    J Neurosurg. 1998 Jun;88(6):1027-43 PMID: 9609298
  172. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease.
    Neurology. 2001 Feb 27;56(4):455-62 PMID: 11222787
  173. Functional properties of AMPA and NMDA receptors expressed in identified types of basal ganglia neurons.
    J Neurosci. 1997 Jan 1;17(1):204-15 PMID: 8987749
  174. The action of N-methyl-D-aspartic acid on mouse spinal neurones in culture.
    J Physiol. 1985 Apr;361:65-90 PMID: 2580984
  175. The role of excitotoxicity and metabolic failure in the pathogenesis of neurological disorders.
    Neurobiology (Bp). 1998;6(1):99-108 PMID: 9713834
  176. Primate models of movement disorders of basal ganglia origin.
    Trends Neurosci. 1990 Jul;13(7):281-5 PMID: 1695404
  177. Excitotoxicity and neurodegenerative diseases.
    Curr Opin Neurol. 1995 Dec;8(6):487-97 PMID: 8845937
  178. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists.
    Nature. 1991 Jan 31;349(6308):414-8 PMID: 1846943
  179. Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by intrastriatal microinjection of dopamine.
    Eur J Pharmacol. 1995 Jan 16;272(2-3):123-9 PMID: 7713155
  180. The AMPAR subunit GluR2: still front and center-stage.
    Brain Res. 2000 Dec 15;886(1-2):190-207 PMID: 11119696
  181. A placebo-controlled, double-blind cross-over trial of adjunctive one month remacemide hydrochloride treatment in patients with refractory epilepsy.
    Seizure. 2000 Dec;9(8):537-43 PMID: 11162750
  182. Role of excitotoxicity in human neurological disease.
    Curr Opin Neurobiol. 1992 Oct;2(5):657-62 PMID: 1422123
  183. Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes.
    Eur J Pharmacol. 1996 Jan 25;296(2):209-13 PMID: 8838458
  184. Turning behaviour and catalepsy after injection of excitatory amino acids into rat substantia nigra.
    Neurosci Lett. 1981 May 29;23(3):337-42 PMID: 7196552
  185. Permeation and block of N-methyl-D-aspartic acid receptor channels by divalent cations in mouse cultured central neurones.
    J Physiol. 1987 Dec;394:501-27 PMID: 2451020
  186. Glycine potentiates the NMDA response in cultured mouse brain neurons.
    Nature. 1987 Feb 5-11;325(6104):529-31 PMID: 2433595
  187. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.
    J Neurophysiol. 1994 Aug;72(2):507-20 PMID: 7983515
  188. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease.
    J Neural Transm Park Dis Dement Sect. 1992;4(1):27-34 PMID: 1347219
  189. Differential subcellular localization of mGluR1a and mGluR5 in the rat and monkey Substantia nigra.
    J Neurosci. 2001 Mar 15;21(6):1838-47 PMID: 11245668
  190. Kainate receptors presynaptically downregulate GABAergic inhibition in the rat hippocampus.
    Neuron. 1997 Oct;19(4):893-901 PMID: 9354335
  191. NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.
    Neurosci Lett. 1992 Aug 17;142(2):179-82 PMID: 1280793
  192. The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist.
    J Neural Transm Park Dis Dement Sect. 1993;5(2):101-6 PMID: 8333906
  193. Pharmacology and functions of metabotropic glutamate receptors.
    Annu Rev Pharmacol Toxicol. 1997;37:205-37 PMID: 9131252
  194. The role of divalent cations in the N-methyl-D-aspartate responses of mouse central neurones in culture.
    J Physiol. 1988 May;399:247-66 PMID: 2457089
  195. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists.
    Eur J Pharmacol. 1993 Mar 2;232(2-3):247-53 PMID: 8385618
  196. Calcium entry through kainate receptors and resulting potassium-channel blockade in Bergmann glial cells.
    Science. 1992 Jun 12;256(5063):1563-6 PMID: 1317969
  197. Abnormalities of the electron transport chain in idiopathic Parkinson's disease.
    Ann Neurol. 1989 Dec;26(6):719-23 PMID: 2557792
  198. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.
    J Neural Transm Suppl. 1994;43:91-104 PMID: 7884411
  199. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat.
    Br J Pharmacol. 2000 Feb;129(3):541-6 PMID: 10711353
  200. Parkinson's disease. First of two parts.
    N Engl J Med. 1998 Oct 8;339(15):1044-53 PMID: 9761807
  201. Unilateral dopamine depletion increases expression of the 2A subunit of the N-methyl-D-aspartate receptor in enkephalin-positive and enkephalin-negative neurons.
    Neuroscience. 2001;103(2):405-12 PMID: 11246155
  202. Intrastriatal injection of a selective metabotropic excitatory amino acid receptor agonist induces contralateral turning in the rat.
    J Pharmacol Exp Ther. 1991 Dec;259(3):1366-70 PMID: 1662277
  203. Block of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors by polyamines and polyamine toxins.
    J Pharmacol Exp Ther. 1996 Aug;278(2):669-78 PMID: 8768718
  204. Models of basal ganglia function and pathophysiology of movement disorders.
    Neurosurg Clin N Am. 1998 Apr;9(2):223-36 PMID: 9495888
  205. [Effects of intravenous administration of memantine in parkinsonian patients (author's transl)].
    Arzneimittelforschung. 1977 Jul;27(7):1487-9 PMID: 332193
  206. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
    Ann Neurol. 1996 May;39(5):574-8 PMID: 8619541
  207. Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: striatum and globus pallidus.
    J Comp Neurol. 1998 Jan 5;390(1):63-74 PMID: 9456176
  208. Role of the strychnine-insensitive glycine binding site in the nucleus accumbens and anterodorsal striatum in sensorimotor gating: a behavioral and microdialysis study.
    Psychopharmacology (Berl). 1997 Mar;130(2):131-8 PMID: 9106910
  209. Ca2+ permeability of KA-AMPA--gated glutamate receptor channels depends on subunit composition.
    Science. 1991 May 10;252(5007):851-3 PMID: 1709304
  210. Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse.
    Eur J Pharmacol. 1995 Jul 4;280(2):159-66 PMID: 7589181
  211. Relationship of activity in the subthalamic nucleus-globus pallidus network to cortical electroencephalogram.
    J Neurosci. 2000 Jan 15;20(2):820-33 PMID: 10632612
  212. Selective antagonism of native and cloned kainate and NMDA receptors by polyamine-containing toxins.
    J Pharmacol Exp Ther. 1993 Sep;266(3):1573-80 PMID: 7690404
  213. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
    Naunyn Schmiedebergs Arch Pharmacol. 1994 Jan;349(1):61-5 PMID: 7908126
  214. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist.
    Pol J Pharmacol. 1995 Nov-Dec;47(6):501-7 PMID: 8868372
  215. Therapeutic brain concentration of the NMDA receptor antagonist amantadine.
    Neuropharmacology. 1995 Jul;34(7):713-21 PMID: 8532138
  216. Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats.
    J Neural Transm Gen Sect. 1994;98(1):57-67 PMID: 7710739
  217. The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists.
    Eur J Pharmacol. 1994 Oct 24;264(2):207-11 PMID: 7851484
  218. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels.
    Eur J Pharmacol. 1989 Aug 3;166(3):591-2 PMID: 2553441
  219. Effects of the antiparkinsonian drug budipine on central neurotransmitter systems.
    Eur J Pharmacol. 1996 Apr 22;301(1-3):67-73 PMID: 8773448
  220. Posteroventral pallidotomy for Parkinson's disease.
    J Neurosurg. 1992 Sep;77(3):487-8 PMID: 1506902
  221. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies.
    Eur J Neurosci. 1996 Jul;8(7):1408-14 PMID: 8758948
  222. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.
    Clin Neuropharmacol. 1999 Sep-Oct;22(5):273-6 PMID: 10516877
Article Info
Journal
Drugs & aging
Abbr.
Drugs Aging
ISSN
1170-229X
DOI
10.2165/00002512-200320050-00006
Published
2003-00-00
Pages
377-97
Language
English
Region
New Zealand
NLM ID
9102074
Subset
IM
External Links
PubMed source DOI: 10.2165/00002512-200320050-00006 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2